BIOCRYST PHARMACEUTICALS, INC.
Asset & Liabilities Breakdown
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
FY2014
FY2013
FY2012
FY2011
FY2010
Asset Breakdown FY2019
Total Assets: $175.3M
Liabilities Breakdown FY2019
Total Liabilities: $137.0M
Asset Breakdown
Total Assets: $175.3M
| Line Item | Value | % of Total |
|---|---|---|
| Cash & Equivalents | $114.2M | 65.1% |
| Accounts Receivable | $22.1M | 12.6% |
| Inventory | $0 | 0.0% |
| Property, Plant & Equipment | $7.3M | 4.2% |
| Goodwill | $0 | 0.0% |
| Intangible Assets | $0 | 0.0% |
| Other Assets | $31.6M | 18.0% |
Liabilities Breakdown
Total Liabilities: $137.0M
| Line Item | Value | % of Total |
|---|---|---|
| Accounts Payable | $14.0M | 10.2% |
| Long-Term Debt | $0 | 0.0% |
| Other Liabilities | $123.0M | 89.8% |